TAK-448
DCTPepD ID DCTPepD0073
Active Ingredients TAK-448
Description A metastin/kisspeptin analog consisting of nine amino acids, have an anti-tumor effect through suppression of androgen hormones (luteinizing hormone and testosterone) levels. Kisspeptin/metastin, a hypothalamic peptide, plays a pivotal role in controlling gonadotropin-releasing hormone (GnRH) neurons.
Synonyms TAK 448; TAK448; RVT-602; 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl) hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide monoacetate; TAK-448
Disease Prostate Cancer, Low Testosterone
Classification
Peptide and derivative
Structure Information
Molecular Formula C58H80N16O14
Molecular Weight 1225.4
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name (2S)-2-[[(2S,4R)-1-[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-N-[(2S,3R)-1-[[(2S)-1-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-[(N'-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]butanediamide
InChI InChI=1S/C58H80N16O14/c1-30(2)22-42(51(82)66-40(16-11-21-63-57(61)62-5)50(81)67-41(49(60)80)25-35-28-64-39-15-10-9-14-38(35)39)70-58(88)73-72-53(84)43(23-33-12-7-6-8-13-33)69-55(86)48(31(3)75)71-52(83)44(27-47(59)79)68-54(85)46-26-37(78)29-74(46)56(87)45(65-32(4)76)24-34-17-19-36(77)20-18-34/h6-10,12-15,17-20,28,30-31,37,40-46,48,64,75,77-78H,11,16,21-27,29H2,1-5H3,(H2,59,79)(H2,60,80)(H,65,76)(H,66,82)(H,67,81)(H,68,85)(H,69,86)(H,71,83)(H,72,84)(H3,61,62,63)(H2,70,73,88)/t31-,37-,40+,41+,42+,43+,44+,45-,46+,48+/m1/s1
InChI_Key MWXWMWSUUYXMRA-GRKBUMBKSA-N
SMILES NC(C[C@H](NC([C@]1([H])C[C@@H](O)CN1C([C@H](NC(C)=O)CC2=CC=C(O)C=C2)=O)=O)C(N[C@@H]([C@H](O)C)C(N[C@H](C(NNC(N[C@H](C(N[C@@H](CCCNC(NC)=N)C(N[C@H](C(N)=O)CC3=CNC4=C3C=CC=C4)=O)=O)CC(C)C)=O)=O)CC5=CC=CC=C5)=O)=O)=O
External Codes
PubChem CID 46700761
DrugBank Accession Number DB11975
NCI Thesaurus Code Not available
UNII YO029HR229 GSRS
CAS 1234319-68-6
Drug approval
Drug indication
TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic Neoplasms, and Hypogonadotropic Hypogonadism.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT02369796 | An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Participants With Hypogonadotropic Hypogonadism | Hypogonadotropic Hypogonadism | Phase 2 | Treatment |
| NCT02381288 | A Randomized, Single-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Stimulatory Effects of TAK-448, a Kisspeptin Analog, Administered Intermittently in Middle-aged and Older Men With Low Testosterone | Low Testosterone | Phase 2 | Treatment |
| NCT01132404 | A Phase 1/2, Open Label Study in Men With Prostate Cancer to Assess the Safety. Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1-Month Depot, Including a Randomized Portion With a Group Administered Leuprorelin | Prostate Cancer; Prostatic Neoplasms | Phase 1/2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
